Safety and Efficacy of KarXT (Xanomeline-Trospium) in Schizophrenia in the Phase 3, Randomized, Double-blind, Placebo-controlled EMERGENT-2 Trial

Neuroscience Education Institute (NEI) Congress; 2022 November 3-6.
Correll, C., Miller, A., et al.
View

Muscarinic Acetylcholine Receptors for Psychotic Disorders: Bench-side to Clinic

Trends Pharmacol Sci. 2022 Dec;43(12):1098-1112.
Yohn, S., Weiden, P., et al.
View

The Potential of M1 Agonists to Treat Cognitive Impairment: Evidence From a Phase 2 Study of KarXT in Schizophrenia (EMERGENT-1)

2022 Schizophrenia International Research Society (SIRS) Annual Congress. 2022 April 6-10.
Harvey, P. D., Sauder, C., et al.
View

KarXT Treatment Improves Cognitive Performance in Cognitively Impaired Patients with Schizophrenia: A Post hoc Analysis of the Phase 2 EMERGENT-1 Study

34th European College of Neuropsychopharmacology (ECNP) Congress; 2021 October 2-5.
Sauder, C., Allen, L., et al.
View

Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia

American Journal of Psychiatry 2022; 21101083
Paul, S., Yohn, S., et al.
View